TITLE:
Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

CONDITION:
Head and Neck Cancer

INTERVENTION:
Motexafin Gadolinium Injection

SUMMARY:

      The purpose of this study is to evaluate the safety of adding the investigational drug
      Motexafin Gadolinium to the standard treatment of radiation therapy and chemotherapy with
      drugs called 5-FU and cisplatin in patients with advanced head and neck cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  At least 18 years of age

          -  Each patient must sign a study-specific informed consent form

          -  Newly diagnosed, locally advanced, non-metastatic Squamous Cell Carcinoma of the Head
             and Neck (SCCHN) arising from a primary site in the oropharynx, hypopharynx, or
             larynx confirmed by evaluation of fine needle aspiration or biopsy samples and MRI

          -  Eligible for curative intent treatment with hyperfractionated radiation and
             concurrent 5-FU and cisplatin

          -  Karnofsky Performance Status score of at least 60%

          -  Primary tumor at least 4 cm in diameter

        Exclusion Criteria:

        Laboratory Values of:

          -  Serum creatinine > 1.8 mg/dL; unless 24-hour urine creatinine clearance is  70
             mL/min

          -  Serum total bilirubin > 1.5 times the upper limit of normal

          -  ALT (formerly SGPT) > 1.5 times the upper limit of normal

          -  Alkaline phosphatase > 1.5 times the upper limit of normal

          -  Absolute neutrophil count (ANC) < 1500/L

          -  Platelet count < 100,000/L

          -  3+ or greater proteinuria on urinalysis

        and

          -  Squamous Cell Carcinoma of the Head and Neck arising from a primary site in the oral
             cavity or nasopharynx

          -  Distant metastases

          -  Prior history of cancer at any site treated with radiotherapy and/or chemotherapy

          -  History of SCCHN diagnosed within 5 years of current diagnosis
      
